PL1924561T3 - 6-aryloalkiloamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiny jako agoniści receptora 5-ht2c - Google Patents

6-aryloalkiloamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiny jako agoniści receptora 5-ht2c

Info

Publication number
PL1924561T3
PL1924561T3 PL06802859T PL06802859T PL1924561T3 PL 1924561 T3 PL1924561 T3 PL 1924561T3 PL 06802859 T PL06802859 T PL 06802859T PL 06802859 T PL06802859 T PL 06802859T PL 1924561 T3 PL1924561 T3 PL 1924561T3
Authority
PL
Poland
Prior art keywords
azepines
arylalkylamino
benzo
tetrahydro
receptor agonists
Prior art date
Application number
PL06802859T
Other languages
English (en)
Inventor
Karin Briner
Bartolome Marta Adeva
Manuel Javier Cases-Thomas
Christopher Stanley Galka
Llorente Alicia Marcos
Maria Angeles Martinez-Grau
Michael Philip Mazanetz
John Cunningham O'toole
Richard Edmund Rathmell
Matthew Robert Reinhard
Selma Sapmaz
Andrew Caerwyn Williams
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1924561T3 publication Critical patent/PL1924561T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06802859T 2005-09-01 2006-09-01 6-aryloalkiloamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiny jako agoniści receptora 5-ht2c PL1924561T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05380191 2005-09-01
US73108105P 2005-10-28 2005-10-28
PCT/US2006/034335 WO2007028083A2 (en) 2005-09-01 2006-09-01 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
EP06802859A EP1924561B1 (en) 2005-09-01 2006-09-01 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists

Publications (1)

Publication Number Publication Date
PL1924561T3 true PL1924561T3 (pl) 2013-03-29

Family

ID=39892208

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06802859T PL1924561T3 (pl) 2005-09-01 2006-09-01 6-aryloalkiloamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiny jako agoniści receptora 5-ht2c

Country Status (13)

Country Link
US (2) US20080269196A1 (pl)
EP (1) EP1924561B1 (pl)
JP (1) JP5155864B2 (pl)
CN (1) CN101258131B (pl)
AU (1) AU2006287202B2 (pl)
BR (1) BRPI0615048A2 (pl)
CA (1) CA2619448C (pl)
DK (1) DK1924561T3 (pl)
ES (1) ES2397400T3 (pl)
PL (1) PL1924561T3 (pl)
PT (1) PT1924561E (pl)
SI (1) SI1924561T1 (pl)
WO (1) WO2007028083A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5237810B2 (ja) * 2005-09-01 2013-07-17 イーライ リリー アンド カンパニー 5−HT2C受容体アゴニストとしての6−置換された2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン
WO2007028132A2 (en) * 2005-09-01 2007-03-08 Eli Lilly And Company 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
WO2007140213A1 (en) 2006-05-26 2007-12-06 Forest Laboratories Holdings Limited Pyridoazepine derivatives
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
EP2285783B1 (en) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
EP2297112B1 (en) 2008-05-06 2013-04-03 Boehringer Ingelheim International GmbH Pyrazole compounds as ccr1 antagonists
UA103634C2 (en) 2008-09-26 2013-11-11 Берингер Ингельхайм Интернациональ Гмбх Azaindazole compounds as ccr1 receptor antagonists
KR20120087923A (ko) 2009-10-21 2012-08-07 베링거 인겔하임 인터내셔날 게엠베하 Ccr1 수용체 길항제로서의 인다졸 및 피라졸로피리딘 화합물
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
CA2782384A1 (en) * 2009-12-08 2011-06-16 Boehringer Ingelheim International Gmbh Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
EP2655371B1 (en) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Pyrazolopiperidine compounds as ccr1 receptor antagonists
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
SI3511319T1 (sl) 2014-07-03 2023-10-30 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
JPWO2017195894A1 (ja) * 2016-05-13 2019-03-14 日産化学株式会社 2−アセチルピリジン化合物の製造方法
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
CN114929235A (zh) * 2020-01-03 2022-08-19 布鲁奥科制药有限公司 用于治疗cns病症的化合物和组合物
GB202101734D0 (en) 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265890A (en) * 1978-07-07 1981-05-05 Smithkline Corporation 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP0285287A3 (en) 1987-03-23 1990-08-16 Smithkline Beecham Corporation 3-benzazepine compounds for use in treating gastrointestinal motility disorders
US4985352A (en) * 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB9116824D0 (en) 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
US5639748A (en) * 1991-08-05 1997-06-17 Smithkline Beecham Corporation 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity
EP0562118B1 (en) 1991-09-11 1998-03-04 Canon Kabushiki Kaisha Improved cleaning member for ink jet head and ink jet device provided with said cleaning member
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
US5698766A (en) * 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
EP1213017A3 (en) 2000-12-05 2003-11-12 Akzo Nobel N.V. Use of a 5-HT2C receptor agonist for the treatment of hot flushes
WO2002074746A1 (fr) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Derives de benzazepine
EP1406902B1 (en) 2001-07-13 2005-10-19 Pharmacia & Upjohn Company LLC Hexahydroazepino[4,5-g]indoles and indolines as 5-ht receptor ligands
CA2468010A1 (en) 2001-11-28 2003-06-05 Pharmacia & Upjohn Company Benzazepine derivatives and their use as 5-ht ligands
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
EP2332919A3 (en) 2003-06-17 2011-10-19 Arena Pharmaceuticals, Inc. Processes for preparing 3-benzazepines
CN1805938B (zh) 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
TW200510324A (en) 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
US20070275949A1 (en) 2003-10-22 2007-11-29 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
DK1720836T3 (da) * 2004-02-25 2014-05-05 Lilly Co Eli 6-substituerede 2,3,4,5-tetrahydro-1h-benzo [d]azepiner som 5-ht2c-receptoragonister
DK1838677T3 (da) 2004-12-21 2010-01-11 Arena Pharm Inc Krystallinske former af (R)-8-chlor-1.methyl-2,3,4,5-tetrahydro-1H-3-benzazepinhydrochlorid
CN102627607A (zh) 2004-12-23 2012-08-08 艾尼纳制药公司 5HT2c受体调节剂组合物和使用方法
JP5237810B2 (ja) * 2005-09-01 2013-07-17 イーライ リリー アンド カンパニー 5−HT2C受容体アゴニストとしての6−置換された2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン

Also Published As

Publication number Publication date
ES2397400T3 (es) 2013-03-06
EP1924561A2 (en) 2008-05-28
AU2006287202B2 (en) 2013-01-24
CN101258131B (zh) 2013-07-24
US20110269745A1 (en) 2011-11-03
PT1924561E (pt) 2013-01-16
SI1924561T1 (sl) 2013-02-28
AU2006287202A1 (en) 2007-03-08
JP2009507034A (ja) 2009-02-19
WO2007028083A3 (en) 2007-05-18
US8680091B2 (en) 2014-03-25
JP5155864B2 (ja) 2013-03-06
AU2006287202A8 (en) 2008-03-13
CA2619448A1 (en) 2007-03-08
DK1924561T3 (da) 2012-12-10
US20080269196A1 (en) 2008-10-30
CA2619448C (en) 2013-08-13
EP1924561B1 (en) 2012-11-14
CN101258131A (zh) 2008-09-03
WO2007028083A2 (en) 2007-03-08
BRPI0615048A2 (pt) 2010-03-30

Similar Documents

Publication Publication Date Title
PT1924561E (pt) Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados
ZA200606580B (en) 6-Substituted 2,3,4,5-tetrahydro-1H-benzo[D]azepines as 5-HT2C receptor agonists
ZA200800512B (en) Substituted tetrahydro-1H-pyrido[4,3,B]indoles as serotonin receptor agonists and antagonists
ZA201001151B (en) 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h-1'h-[1,4']bipyridinyl-2'-ones
HK1133635A1 (en) Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3- benzazepine and intermediates thereof (r)-8--1--2345--1h-3-
ZA200702209B (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
GB0509275D0 (en) Synthetic receptor
ZA200804301B (en) 1,5-substituted indol-2-yl amide derivatives
SI1805163T1 (sl) 1.1a,5,5a-tetrahidro-3-tia-ciklopropa(a)pentaleni: tricikliäśni tiofenski derivati kot agonisti receptorja s1p1/edg1
AP2008004441A0 (en) Piperdin-4-ylpyrazin-2-ylamine derivatives as fastdissociating dopamine 2 receptor antagonists
AP2008004602A0 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
EP2017281A4 (en) AGONISTS AT TOLL-LIKE RECEPTOR 9
ZA200805915B (en) Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof
EP2094695A4 (en) TETRAHYDRO-5H-PYRIDO [2,3-D] AZEPINES AS 5-HT2C LIGANDS
ZA200907416B (en) Pyrimido [4,5-D] azepine derivatives as 5-HT2C agonists
GB0509276D0 (en) Synthetic receptor
ZA200803332B (en) Novel parenteral carbamazepine formulation
GB0526099D0 (en) "Hook"
IL197149A0 (en) 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4] diazepine derivatives
HK1131603A1 (en) Selective tr-beta 1 agonist
IL188111A0 (en) 2,5-bis-diamimne [1,4] benzoquinone-derivatives
EP1809296A4 (en) NEW [1,4] -BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS
ZA200710465B (en) Thiophene compounds and thrombopoletin receptor activators
GB0615168D0 (en) Dan's Mug